Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682481 | 1.00 | MME (0.56) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL4919342 | 1.00 | MME (0.56) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL28993693 | 1.00 | MME (0.56) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL10663912 | 0.93 | MME (0.55) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL3629055 | 0.92 | SMN1; SMN2 (0.60) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL10664753 | 0.92 | SMN1; SMN2 (0.60) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL13439529 | 0.92 | SMN1; SMN2 (0.60) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL10192703 | 0.92 | KYNU (0.58) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL2083704 | 0.92 | KYNU (0.58) | MMEECE1SMN1; SMN2CTSKCTSL | |
| SCHEMBL10074198 | 0.92 | KYNU (0.58) | MMEECE1SMN1; SMN2CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163354-B | Preparation method of N-fluorenylmethoxycarbonyl-N-trityl-L-asparagine | 常州吉恩药业有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230026277-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE | MICROX CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| CN-114760995-A | Composition for preventing, alleviating or treating respiratory diseases | 微艾克斯有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114163354-A | Preparation method of N-fluorenylmethoxycarbonyl-N-trityl-L-asparagine | 常州吉恩药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021107547-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE | 단디바이오사이언스 주식회사 | 2021-06-03 | — | — | WO | disclosed |
| US-20080090916-A1 | 2-Amino-4-[(1S,2R)-2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethylcarbamoyl]butyric acid, aka gamma-L-glutamyl-1R,2S-methoxamine; prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active form; transdermal administration; coupling methoxamine with glutamic acid alcohol | NORGINE EUROPE B.V. (NL) | 2008-04-17 | — | — | US | disclosed |
| EP-1841728-A1 | COMPOUNDS FOR TREATING URINARY INCONTINENCE | Norgine Europe BV (NL) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006079809-A1 | COMPOUNDS FOR TREATING URINARY INCONTINENCE | NORGINE EUROPE BV (NL) | 2006-08-03 | — | — | WO | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026277-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE | RELA, CSNK2A1, CSNK1G1 | MME 3168/4885ECE1 2814/4885SMN1; SMN2 3193/4885 |
| US-20080090916-A1 | 2-Amino-4-[(1S,2R)-2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethylcarbamoyl]butyric acid, aka gamma-L-glutamyl-1R,2S-methoxamine; prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active form; transdermal administration; coupling methoxamine with glutamic acid alcohol | GLS, GLRB, CHRM1 | MME 1160/4885ECE1 1541/4885SMN1; SMN2 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.